Literature DB >> 3950673

Lymph node aspiration in the management of Hodgkin's disease.

E Dmitrovsky, S E Martin, A G Krudy, E W Chu, E S Jaffe, D L Longo, R C Young.   

Abstract

Diagnosing recurrent Hodgkin's disease is an important oncologic problem. When relapse does not occur in peripheral nodal sites, then a major surgical exploration is often considered. Lymph node aspiration is proposed as a less invasive approach capable of establishing a diagnosis in some instances. In this retrospective study, 19 patients with Hodgkin's disease underwent 64 lymph node aspirations. Of these patients, 17 had suspected Hodgkin's disease with involvement at an inaccessible site. Two patients with a primary diagnosis of Hodgkin's disease underwent aspiration of a peripheral site. Of these 19 patients, five (26.3%) had a positive aspirate and only two (10.5%) had an unsatisfactory aspirate. No patient had a false-positive aspirate. Of 15 patients with a negative aspirate, five (33%) had a false-negative aspirate. In no case did a false-negative aspirate delay appropriate therapy. In those patients with a positive aspirate, surgical exploration was avoided. We conclude that lymph node aspiration cytology is useful as an initial step to document clinical relapse of Hodgkin's disease at a site that might require a major surgical procedure for diagnosis.

Entities:  

Mesh:

Year:  1986        PMID: 3950673     DOI: 10.1200/JCO.1986.4.3.306

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  2 in total

Review 1.  Percutaneous lymph node biopsy.

Authors:  D D Lawrence; C H Carrasco; B Fornage; N Sneige; S Wallace
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jan-Feb       Impact factor: 2.740

2.  Investigating lymphadenopathy--report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital.

Authors:  R K Gregory; D Cunningham; T A Fisher; P Rhys-Evans; G W Middleton; L Bishop; A Wotherspoon; P A Trott; A G Nash
Journal:  Postgrad Med J       Date:  2000-09       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.